Stockreport
U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
) -- U.S. stock-index futures rose as some investors deemed that Monday’s equity rout brought prices to attractive levels amid speculation that a drug to treat the novel coronavirus may be on the horizon. S&P 500 Index futures contracts expiring in March rose 0.2% at 10:34 a.m. in London, while contracts climbed 0.1% for the Dow Jones Industrial Average and advanced 0.3% for the Nasdaq 100. In Europe, the Stoxx 600 Index erased earlier gains and fell 0.8%, with carmakers being the worst perfomers and banks also underperforming. All three main U.S. stock benchmarks fell more than 3% Monday on growing concern that the coronavirus is spreading more widely outside China. The S&P 500 fell the most since February 2018 and now has declined three straight days, its longest losing streak since December. U.S. stocks have lost about $1 trillion in value in the past two sessions. Japan’s stock market, which was closed Monday, also slid more than 3% Tuesday. “U.S. futures are going up a little on
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance[Business Wire]
- Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial [Yahoo! Finance][Yahoo! Finance]
- Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial[Business Wire]
- Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Wolfe Research.[MarketBeat]
- More
GILD
SEC Filings
SEC Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- GILD's page on the SEC website
- More